Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease

NCT02114203 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Phase 1 Sickle Cell

Interventions

DRUG: PDE9i
DRUG: PDE9i
DRUG: placebo for PDE9i
DRUG: PDE9i

Sponsor

Pfizer